Kaolin Imerys Grolleg Powder - UK
Kaolin Imerys Grolleg Powder - UK
Kaolin Imerys Grolleg Powder - UK
1.2. Relevant identified uses of the substance or mixture and uses advised against
Identified uses Main applications - non-exhaustive list: Ceramics (sanitaryware, floor tiles, wall tiles, roof tiles,
tiles; porcelain, tableware, refractories, etc.)
Human health This product does not meet the criteria for classification as hazardous as defined in the
Regulation EC 1272/2008. Depending on the type of handling and use (e.g. grinding, drying),
airborne respirable crystalline silica may be generated. Prolonged and/or massive inhalation
of respirable crystalline silica dust may cause lung fibrosis, commonly referred to as silicosis.
Principal symptoms of silicosis are cough and breathlessness. Occupational exposure to
respirable crystalline silica dust should be monitored and controlled.
Physicochemical This product is an inorganic substance and does not meet the criteria for PBT or vPvB in
accordance with Annex XIII of REACH. This product should be handled with care to avoid
dust generation.
1/7
Revision date: 01/06/2015 Revision: 5
Grolleg™ Powder
3.2. Mixtures
KAOLIN 100%
CAS number: 1332-58-7 EC number: 310-194-1
The Full Text for all R-Phrases and Hazard Statements are Displayed in Section 16.
Composition comments Impurities:,Quartz: CAS-No.: 14808-60-7 EC No.: 238-878-4.,This product contains
less than 1% quartz (fine fraction); quartz (fine fraction) is classified as STOT RE1.
Inhalation Move affected person to fresh air and keep warm and at rest in a position comfortable for
breathing. Get medical attention if any discomfort continues.
Ingestion Rinse mouth thoroughly with water. Get medical attention if any discomfort continues.
Skin contact Wash skin thoroughly with soap and water. Use suitable lotion to moisturise skin.
Eye contact Do not rub eye. Rinse with copious quantities of water and seek medical attention if irritation
persists.
4.2. Most important symptoms and effects, both acute and delayed
General information Get medical attention promptly if symptoms occur after washing.
4.3. Indication of any immediate medical attention and special treatment needed
Notes for the doctor No specific recommendations.
2/7
Revision date: 01/06/2015 Revision: 5
Grolleg™ Powder
Eye/face protection Eyewear complying with an approved standard should be worn if a risk assessment indicates
eye contact is possible. The following protection should be worn: Chemical splash goggles or
face shield. Contact lenses should not be worn when working with this product.
Hand protection Chemical-resistant, impervious gloves complying with an approved standard should be worn if
a risk assessment indicates skin contact is possible. It is recommended that gloves are made
of the following material: Polyvinyl chloride (PVC). Rubber (natural, latex).
3/7
Revision date: 01/06/2015 Revision: 5
Grolleg™ Powder
Other skin and body No specific requirement. Appropriate protection (e.g. protective clothing, barrier cream) is
protection recommended for workers who suffer from dermatitis or sensitive skin.
Hygiene measures When using do not eat, drink or smoke. Wash hands at the end of each work shift and before
eating, smoking and using the toilet. Use appropriate skin cream to prevent drying of skin.
Respiratory protection In case of prolonged exposure to airborne dust concentrations, wear a respiratory protective
equipment that complies with the requirements of European or national legislation.
Colour White/off-white.
10.1. Reactivity
Reactivity There are no known reactivity hazards associated with this product.
General information This product has low toxicity. Only large quantities are likely to have adverse effects on
human health.
4/7
Revision date: 01/06/2015 Revision: 5
Grolleg™ Powder
Ecotoxicity The product components are not classified as environmentally hazardous. However, large or
frequent spills may have hazardous effects on the environment.
12.1. Toxicity
Acute toxicity - fish LC₅₀, 96 hours: >1000 mg/l, Fish
Disposal methods Where possible, recycling is preferable to disposal. Can be disposed of in compliance with
local regulations.
General No special precautions. The product is not covered by international regulations on the
transport of dangerous goods (IMDG, IATA, ADR/RID).
14.1. UN number
No information required.
5/7
Revision date: 01/06/2015 Revision: 5
Grolleg™ Powder
14.7. Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code
Transport in bulk according to No information required.
Annex II of MARPOL 73/78
and the IBC Code
15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture
National regulations EH40/2005 Workplace exposure limits.
6/7
Revision date: 01/06/2015 Revision: 5
Grolleg™ Powder
General information Workers must be informed of the presence of crystalline silica and trained in the proper use
and handling of this product as required under applicable regulations. A multi-sectoral social
dialogue agreement on Workers Health Protection through the Good Handling and Use of
Crystalline Silica and Products Containing it was signed on 25 April 2006. This autonomous
agreement, which receives the European Commission’s financial support, is based on a Good
Practices Guide. The requirements of the Agreement came into force on 25 October 2006.
The Agreement was published in the Official Journal of the European Union (2006/C 279/02).
The text of the Agreement and its annexes, including the Good Practices Guide, are available
from http://www.nepsi.eu and provide useful information and guidance for the handling of
products containing crystalline silica (fine fraction). Literature references are available on
request from EUROSIL, the European Association of Industrial Silica Producers. Prolonged
and/or massive exposure to respirable crystalline silica-containing dust may cause silicosis, a
nodular pulmonary fibrosis caused by deposition in the lungs of fine respirable particles of
crystalline silica. In 1997, IARC (the International Agency for Research on Cancer) concluded
that crystalline silica inhaled from occupational sources can cause lung cancer in humans.
However it pointed out that not all industrial circumstances, nor all crystalline silica types,
were to be incriminated. (IARC Monographs on the evaluation of the carcinogenic risks of
chemicals to humans, Silica, silicates dust and organic fibres, 1997, Vol. 68, IARC, Lyon,
France.) In June 2003, SCOEL (the EU Scientific Committee on Occupational Exposure
Limits) concluded that the main effect in humans of the inhalation of respirable crystalline
silica dust is silicosis. “There is sufficient information to conclude that the relative risk of lung
cancer is increased in persons with silicosis (and, apparently, not in employees without
silicosis exposed to silica dust in quarries and in the ceramic industry). Therefore preventing
the onset of silicosis will also reduce the cancer risk…“ (SCOEL SUM Doc 94-final, June
2003). So there is a body of evidence supporting the fact that increased cancer risk would be
limited to people already suffering from silicosis. Worker protection against silicosis should be
assured by respecting the existing regulatory occupational exposure limits and implementing
additional risk management measures where required. . Health & Safety Executive: Detailed
reviews of the scientific evidence on the health effects of crystalline silica have been
published by HSE (Health and Safety Executive, UK) in the Hazard Assessment Documents
EH75/4 (2002) and EH75/5 (2003). The HSE points out on its website that “Workers exposed
to fine dust containing quartz are at risk of developing a chronic and possibly severely
disabling lung disease known as "silicosis"." In addition to silicosis, there is now evidence that
heavy and prolonged workplace exposure to dust containing crystalline silica can lead to an
increased risk of lung cancer. The evidence suggests that an increased risk of lung cancer is
likely to occur only in those workers who have developed silicosis. . .
Revision 5
Such information is to the best of IMERYS knowledge and believed accurate and reliable as of the date indicated. However,
no representation, warranty or guarantee is made to its accuracy, reliability or completeness. It is the user’s responsibility to
satisfy himself as to the suitability and completeness of such information for his own particular use.
7/7